Diversified Platform Opportunities Sorrento's proprietary G-MAB library combined with multiple delivery modalities including CAR-T, DAR-T, ADCs, oncolytic Seprehvec, lymphatic targeting SOFUSA and bispecific approaches creates licensing and co development opportunities across oncology, autoimmune, inflammatory, viral, and neurodegenerative spaces. This breadth supports partnerships with pharma seeking next generation therapies, as well as opportunities to monetize pain management candidates RTX and SEMDEXA through strategic collaborations or out licensing.

Diagnostic & Therapeutic Synergy In addition to therapeutics, Sorrento's COVID-19 related assets including COVISTIX, COVITRACK, COVI-SHIELD, COVI-AMG, COVI-MSC and the rapid testing instrument development funded by NIAID position the company for diagnostic collaborations, lab networks, and public health partnerships, including potential contracted manufacturing or platform licensing for labs and providers.

Financial Restructuring Tailwinds Recent Chapter 11 proceedings and historical financing pressures signal a need for strategic deals to de-risk and monetize assets. Business development opportunities may include milestone driven licensing, asset sales, or collaborations with capable strategic investors to advance pipeline programs without heavy upfront risk.

Strategic Geographic Position Based in San Diego, Sorrento sits in a dense biotech cluster with access to contract manufacturers, CROs, clinical trial networks, and talent. This enables efficient partner outreach, co development pilots, and regional supply arrangements that can shorten development timelines and reduce costs for potential licensees or co development partners.

IP & Innovation Leverage The depth of the G-MAB library and versatile delivery modalities offers a compelling basis for IP licensing, co development, or sponsored research deals. Target partners include large oncology players, specialty pharma focusing on autoimmune and neurodegenerative diseases, and firms seeking novel viral or bispecific platforms, with clear milestones and potential for multiple program collaboration.